D Orazio & Associates Inc. Has $710,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

D Orazio & Associates Inc. lowered its position in Novo Nordisk A/S (NYSE:NVO) by 4.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,249 shares of the company’s stock after selling 401 shares during the period. D Orazio & Associates Inc.’s holdings in Novo Nordisk A/S were worth $710,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at $42,000. Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the 3rd quarter worth $48,000. Dunhill Financial LLC raised its stake in shares of Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after purchasing an additional 311 shares during the period. Finally, Albion Financial Group UT lifted its holdings in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $86.39 on Friday. The stock has a market cap of $387.66 billion, a P/E ratio of 26.26, a P/E/G ratio of 0.96 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.75. The company has a fifty day moving average price of $91.86 and a two-hundred day moving average price of $111.83. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.